Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung epithelial cells

Wen et al., Journal of Molecular Cell Biology, doi:10.1093/jmcb/mjad048
Jul 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 419 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19hcq.org
In Vitro and mouse study showing that activating α7 nAChR with the agonist GTS-21 reduced oxidative stress and inflammation, and reduced live virus infection in lung epithelial cells.
The results provide some mechanistic insight into how HCQ may inhibit SARS-CoV-2 infection, by acting through the α7 nAChR pathway. Previous in silico studies predict HCQ blocks SARS-CoV-2 binding to both ACE2 and α7 nAChR. This study provides experimental evidence that activating α7 nAChR decreases ACE2 expression and reduces SARS-CoV-2 infection.
Activating the α7 nAChR pathway (with agonists) or protecting it from viral interference (with HCQ for example) could be viable therapeutic approaches against COVID-19.
38 preclinical studies support the efficacy of HCQ for COVID-19:
Wen et al., 25 Jul 2023, peer-reviewed, 5 authors. Contact: zhaojincun@gird.cn, xsu@ips.ac.cn.
This PaperHCQAll
Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung epithelial cells
Jing Wen, Jing Sun, Yanhong Tang, Jincun Zhao, Xiao Su
doi:10.1093/jmcb/mjad048/7231085
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19) has caused more than 6 million deaths and poses a huge threat to the global economy and public health. SARS-CoV-2 enters lung epithelial cells depending on S protein binding with angiotensin converting enzyme 2 (ACE2). In-silico studies have shown that both SARS-CoV and SARS-CoV-2 S glycoproteins can interact with the extracellular domain of α7 nicotinic acetylcholine receptor (nAChR). Hydroxychloroquine, a known SARS-CoV-2 inhibitor, acts at the entry stage of SARS-CoV-2 by blocking the virus-binding sites on the two receptors, ACE2 and α7 nAChR (Navya and Hosur, 2021). Given that α7 nAChR possesses anti-inflammatory effects and could interact with the SARS-CoV-2 S protein,
References
Azabou, Bao, Bounab, Vagus Nerve Stimulation: A Potential Adjunct Therapy for COVID-19, Frontiers in medicine
Bonaz, Sinniger, Pellissier, Targeting the cholinergic anti-inflammatory pathway with vagus nerve stimulation in patients with Covid-19?, Bioelectronic medicine
Hsieh, Wang, Wu, Reactive Oxygen Species-Dependent c-Fos/Activator Protein 1 Induction Upregulates Heme Oxygenase-1 Expression by Bradykinin in Brain Astrocytes, Antioxidants & redox signaling
Kipshidze, Chekanov, Kipshidze, Transpulmonary electrotherapy for reduction of lung viral load of SARS-CoV-2 in patients with COVID-19, Medical hypotheses
Kox, Pompe, Peters, alpha7 nicotinic acetylcholine receptor agonist GTS-21 attenuates ventilator-induced tumour necrosis factor-alpha production and lung injury, Br J Anaesth
Li, Li, Wang, SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K/AKT/mTOR signaling, Biochimica et biophysica acta. Molecular basis of disease
{ 'indexed': {'date-parts': [[2023, 7, 27]], 'date-time': '2023-07-27T04:29:17Z', 'timestamp': 1690432157617}, 'reference-count': 0, 'publisher': 'Oxford University Press (OUP)', 'license': [ { 'start': { 'date-parts': [[2023, 7, 26]], 'date-time': '2023-07-26T00:00:00Z', 'timestamp': 1690329600000}, 'content-version': 'am', 'delay-in-days': 1, 'URL': 'https://creativecommons.org/licenses/by/4.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.1093/jmcb/mjad048', 'type': 'journal-article', 'created': {'date-parts': [[2023, 7, 26]], 'date-time': '2023-07-26T03:39:02Z', 'timestamp': 1690342742000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung ' 'epithelial cells', 'prefix': '10.1093', 'author': [ { 'given': 'Jing', 'family': 'Wen', 'sequence': 'first', 'affiliation': [ { 'name': 'Unit of Respiratory Infection and Immunity, Institut Pasteur of ' 'Shanghai, Chinese Academy of Sciences , Shanghai 200031 , China'}, { 'name': 'CAS Key Laboratory of Molecular Virology and Immunology, ' 'Institut Pasteur of Shanghai, Chinese Academy of Sciences , ' 'Shanghai 200031 , China'}, { 'name': 'University of Chinese Academy of Sciences , Beijing 100049 , ' 'China'}]}, { 'given': 'Jing', 'family': 'Sun', 'sequence': 'additional', 'affiliation': [ { 'name': 'State Key Laboratory of Respiratory Disease, National Clinical ' 'Research Centre for Respiratory Disease, Guangzhou Institute of ' 'Respiratory Health, the First Affiliated Hospital of Guangzhou ' 'Medical University , Guangzhou 510120 , China'}]}, { 'given': 'Yanhong', 'family': 'Tang', 'sequence': 'additional', 'affiliation': [ { 'name': 'State Key Laboratory of Respiratory Disease, National Clinical ' 'Research Centre for Respiratory Disease, Guangzhou Institute of ' 'Respiratory Health, the First Affiliated Hospital of Guangzhou ' 'Medical University , Guangzhou 510120 , China'}]}, { 'given': 'Jincun', 'family': 'Zhao', 'sequence': 'additional', 'affiliation': [ { 'name': 'State Key Laboratory of Respiratory Disease, National Clinical ' 'Research Centre for Respiratory Disease, Guangzhou Institute of ' 'Respiratory Health, the First Affiliated Hospital of Guangzhou ' 'Medical University , Guangzhou 510120 , China'}]}, { 'ORCID': 'http://orcid.org/0000-0002-8692-8365', 'authenticated-orcid': False, 'given': 'Xiao', 'family': 'Su', 'sequence': 'additional', 'affiliation': [ { 'name': 'Unit of Respiratory Infection and Immunity, Institut Pasteur of ' 'Shanghai, Chinese Academy of Sciences , Shanghai 200031 , China'}, { 'name': 'CAS Key Laboratory of Molecular Virology and Immunology, ' 'Institut Pasteur of Shanghai, Chinese Academy of Sciences , ' 'Shanghai 200031 , China'}, { 'name': 'University of Chinese Academy of Sciences , Beijing 100049 , ' 'China'}]}], 'member': '286', 'published-online': {'date-parts': [[2023, 7, 25]]}, 'container-title': 'Journal of Molecular Cell Biology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://academic.oup.com/jmcb/advance-article-pdf/doi/10.1093/jmcb/mjad048/50961624/mjad048.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/jmcb/advance-article-pdf/doi/10.1093/jmcb/mjad048/50961624/mjad048.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 7, 26]], 'date-time': '2023-07-26T03:39:03Z', 'timestamp': 1690342743000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/jmcb/advance-article/doi/10.1093/jmcb/mjad048/7231085'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 7, 25]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1093/jmcb/mjad048', 'relation': {}, 'ISSN': ['1674-2788', '1759-4685'], 'subject': ['Cell Biology', 'Genetics', 'Molecular Biology', 'General Medicine'], 'published': {'date-parts': [[2023, 7, 25]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit